November 2015

New Product - Ozurdex

Ozurdex (dexamethasone) is an intravitreal implant indicated for the treatment of diabetic macular oedema (DME). It is contraindicated in the following conditions: patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases; patients with advanced glaucoma; aphakic eyes with rupture of the posterior lens capsule, and in eyes with an anterior chamber intraocular lens (ACIOL), iris or transscleral fixated IOLs, and rupture of the posterior lens capsule. Ozurdex is available as an intravitreal implant containing 700 microgram of dexamethasone.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au